These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 21933446)

  • 1. Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B.
    Yeh CT; Chen T; Hsu CW; Chen YC; Lai MW; Liang KH; Chen TC
    BMC Cancer; 2011 Sep; 11():398. PubMed ID: 21933446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation.
    Zhao L; Li X; Cheng Y; Chen R; Shao J; Zhou Y; Li Q; Liao H; Zhao Y; Liu L; Su H; Liu Y; Liu Y; Xu D
    Antiviral Res; 2018 Jun; 154():26-34. PubMed ID: 29630974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.
    Chen CH; Wang JH; Lu SN; Hu TH; Hung CH; Chang MH; Changchien CS; Lee CM
    Antivir Ther; 2012; 17(4):701-9. PubMed ID: 22358132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleos(t)ide analogues causes HBV S gene mutations and carcinogenesis.
    Wang ML; Tang H
    Hepatobiliary Pancreat Dis Int; 2016 Dec; 15(6):579-586. PubMed ID: 27919846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral efficacy of entecavir for hepatitis B virus rtA181V/T mutants.
    Li P; Geng J; Li W; Xu X; Zhang X; Zheng W; Yu Y; Yang Z; Wang M
    Virol J; 2017 Apr; 14(1):68. PubMed ID: 28376852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.
    Yatsuji H; Suzuki F; Sezaki H; Akuta N; Suzuki Y; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Watahiki S; Iwasaki S; Kobayashi M; Kumada H
    J Hepatol; 2008 Jun; 48(6):923-31. PubMed ID: 18433925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant.
    Lai MW; Yeh CT
    Antivir Ther; 2008; 13(7):875-9. PubMed ID: 19043921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection.
    Kurokawa M; Hiramatsu N; Oze T; Yakushijin T; Miyazaki M; Hosui A; Miyagi T; Yoshida Y; Ishida H; Tatsumi T; Kiso S; Kanto T; Kasahara A; Iio S; Doi Y; Yamada A; Oshita M; Kaneko A; Mochizuki K; Hagiwara H; Mita E; Ito T; Inui Y; Katayama K; Yoshihara H; Imai Y; Hayashi E; Hayashi N; Takehara T
    J Gastroenterol; 2012 May; 47(5):577-85. PubMed ID: 22231575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment.
    Margeridon-Thermet S; Svarovskaia ES; Babrzadeh F; Martin R; Liu TF; Pacold M; Reuman EC; Holmes SP; Borroto-Esoda K; Shafer RW
    Antimicrob Agents Chemother; 2013 Jan; 57(1):343-9. PubMed ID: 23114756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma.
    Shin HS; Kim SU; Park JY; Kim DY; Han KH; Chon CY; Baatarkhuu O; Ahn SH
    J Gastroenterol Hepatol; 2012 Sep; 27(9):1528-34. PubMed ID: 22497450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical emergence features and implications of hepatitis B virus rtA181T mutation].
    Li X; Jiang L; Li F; Liu Y; Dai J; Zhao P; Qin Y; Li J; Xu D
    Zhonghua Gan Zang Bing Za Zhi; 2015 Jan; 23(1):23-7. PubMed ID: 25751382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance.
    Elefsiniotis I; Buti M; Jardi R; Vezali E; Esteban R
    Eur J Intern Med; 2009 Sep; 20(5):478-81. PubMed ID: 19712848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients].
    Cho JH; Cheong JY; Kang JK; Park JS; Lee MH; Lim NK; Hong SP; Kim SO; Yoo WD; Cho SW
    Korean J Hepatol; 2008 Mar; 14(1):58-66. PubMed ID: 18367858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.
    Li X; Liu Y; Zhao P; Wang Y; Chen L; Xin S; Zhang XX; Xu D
    Antivir Ther; 2015; 20(2):141-7. PubMed ID: 24992206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
    Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
    World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene.
    Ahn SH; Park YK; Park ES; Kim JH; Kim DH; Lim KH; Jang MS; Choe WH; Ko SY; Sung IK; Kwon SY; Kim KH
    J Virol; 2014 Jun; 88(12):6805-18. PubMed ID: 24696492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma.
    Yang HI; Yeh SH; Chen PJ; Iloeje UH; Jen CL; Su J; Wang LY; Lu SN; You SL; Chen DS; Liaw YF; Chen CJ;
    J Natl Cancer Inst; 2008 Aug; 100(16):1134-43. PubMed ID: 18695135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Core promoter mutant HBV non-responding to adefovir after viral breakthrough on lamivudine: rapid virologic response to tenofovir plus lamivudine in a cirrhotic patient.
    Katsounas A; Jochum C; Canbay A; Schlaak J; Gerlich WH; Gerken G
    Eur J Med Res; 2008 Oct; 13(10):472-5. PubMed ID: 19008175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    Intervirology; 2008; 51(6):385-93. PubMed ID: 19229115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B.
    Cha CK; Kwon HC; Cheong JY; Cho SW; Hong SP; Kim SO; Yoo WD
    J Med Virol; 2009 Mar; 81(3):417-24. PubMed ID: 19152409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.